Date
2022-01Journal
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of AmericaPublisher
Oxford University PressType
Article
Metadata
Show full item recordAbstract
TO THE EDITOR—We agree that optimal drug doses in those ≥12 years of age have been similar to those identified for adults [1, 2]. Neither of our articles addressed the complexity of pediatric drug development [3, 4]. Importantly, the bar for vaccine licensure in healthy children is different from that for administration of a potentially lifesaving therapeutic. In addition, classic pharmacokinetic data (eg, clearance, volume of distribution) do not exist for locally administered vaccines. As such, we need to determine the vaccine dose and schedule from clinical trial data. While we can use “our present understanding of the developing human body” [2] as a starting point for rational clinical trials, we owe our children data on which to base vaccine licensure...Identifier to cite or link to this item
http://hdl.handle.net/10713/17882ae974a485f413a2113503eed53cd6c53
10.1093/cid/ciab400